Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Next-Generation Therapeutics for Infectious Diseases Conquer the Global Spotlight

Published: Thursday, March 27, 2014
Last Updated: Thursday, March 27, 2014
Bookmark and Share
Resistance to current drugs spurs treatment innovation in influenza, respiratory syncytial virus, chlamydia and gonorrhea.

The available antivirals for commonly occurring infections such as respiratory syncytial virus (RSV) and influenza are characterized by variable response, poor tolerability and suboptimal dosing regimens, limiting their regular use and efficacy.

Likewise, the development of resistance to almost every recommended antibiotic for bacterial infections like chlamydia and gonorrhoea makes treatment complicated.

Successful commercialization of next-generation therapeutics and the imminent arrival of novel innovative vaccine technologies are expected to address these issues and generate strong growth in the infectious diseases therapeutics market.

New analysis from Frost & Sullivan’s Global Infectious Diseases Therapeutics Market-Influenza, RSV, Chlamydia, and Gonorrhoea finds the influenza vaccine industry is witnessing a shift from conventional egg-based vaccines, which use live attenuated and inactivated viruses, to novel DNA-based, recombinant, sub-unit, and even microbial vector-based approaches. These technologies are becoming popular for their cost benefits and potential for mass production in the event of a pandemic.

“Several new antiviral agents, including short-interfering ribonucleic acids (siRNAs), antimicrobial peptides, and other anti-inflammatory drugs, are being evaluated in clinical trials for viral infections,” said Frost & Sullivan Healthcare Senior Research Analyst Aiswariya Chidambaram. “These ongoing clinical programs targeting newer classes of antivirals, vaccine technologies and improved diagnosis are likely to result in more sophisticated levels of treatment.”

While resistance to current drugs and viral/bacterial breakthrough remain key obstacles to effective treatment, the asymptomatic nature of sexually transmitted bacterial infections makes even diagnosis difficult. In many cases, genital infections caused by Chlamydia trachomatis and Neisseria gonorrhoea go unnoticed, as they are asymptomatic in up to 70 percent of infected women and up to 50 percent of infected men.

“Since preventative therapies can help control infectious diseases effectively, vaccines are the way forward, particularly for viral infections,” noted Chidambaram. “In fact, the global infectious diseases therapeutics market will be geared in this direction, as a way to significantly control disease burden.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Disruptive Technologies Transforming the Growing Biologic Manufacturing Market
Single use technologies are paving the future of biopharmaceutical manufacturing.
Wednesday, June 22, 2016
Can Regenerative Medicine be the Cure for Cancer and Other Deadly Diseases?
Change in regulatory frameworks and standards are essential to expedite approval and release of innovative products.
Thursday, June 19, 2014
Strong Pipeline of mAbs Biosimilars in the US and Europe Lends Impetus to Global Market
The market is expected to soar from $1.2 billion of 2013 to $24 billion in 2019.
Tuesday, February 04, 2014
Bright Future Ahead for Biopharmaceutical Contract Manufacturing, Says Frost & Sullivan
New market insight uncovers the latest technology trends and strategic approaches for biopharma CMOs.
Tuesday, October 01, 2013
Molecular Farming Fits Need for Fully Functional Protein Therapeutics and Low-Cost Vaccines
Technology gains momentum through collaborations and licensing deals.
Monday, June 24, 2013
Frost & Sullivan Predicts Growth for the European Vaccines Market
Technology innovation and increasing focus on new vaccine development are likely to revolutionize the vaccine industry from prophylactic to therapeutic vaccines.
Friday, February 01, 2013
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
The Power Of Orthogonality In Assessing The Stability Of Biopharmaceuticals
By utilizing orthogonal techniques, researchers can maximize the secure application of all analytical results generated.
Dysfunction in Neuronal Transport Mechanism Linked to Alzheimer’s
Findings confirm mutation-caused problem but also reveal a new therapeutic target.
New Antibody Therapy Permanently Blocks SIV Infection
An international research team has developed an effective treatment strategy against the HIV-like Simian Immunodeficiency Virus (SIV) in rhesus macaques.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Zika Vaccines Prevent Disorders in Newborn Mice
Disorder immunity transmitted from female mice to pups following vaccination with two Zika vaccines.
Antibody Drug Conjugates May Help Personalize Radiotherapy
Biomarker-driven study shows promise in sensitizing HER2 positive tumors to radiation and chemotherapy.
DNA Vaccines Protect Monkeys Against Zika Virus
Two experimental Zika virus DNA vaccines developed by NIH scientists protected monkeys against Zika infection.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos